利尔化学股份有限公司 证券代码：002258 证券简称：利尔化学 利尔化学股份有限公司投资者关系活动记录表 编号：2023-01 投资者关系活动 特定对象调研 □分析师会议 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 海通证券：李智；四川发展证券基金：肖柏辰；弘尚资产：沙 人员姓名 正江；申万资管：许维伦；华能贵诚信托：赵文 时间 2023 年 7 月 19 日 地点 公司会议室 上市公司接待人 副总经理/董事会秘书：刘军 员姓名 董事会办公室：马媛 1、公司如何看待草铵膦市场？ 答：今年以来受竞争加剧以及农化行业周期的影响，公司 主要产品草铵膦价格下降较大，对公司业绩产生了较大的影 响。公司一直都看好草铵膦市场的成长空间，并全力保持竞争 优势。 2、公司精草铵膦项目的实施情况？ 答：目前公司正在按照建设计划有序推进，湖南津市 2 万 投资者关系活动 吨/年酶法精草铵膦项目预计 7 月开始试生产，荆州 1 万吨/ 主要内容介绍 年生化法精草铵膦项目已于今年 2 月获批开建。同时，公司加 快实施精草铵膦在海外多个国家的登记和市场布局工 ...

Financial Performance - The company's revenue for Q1 2023 was ¥2,442,238,961.34, a decrease of 6.53% compared to ¥2,612,935,661.17 in the same period last year[5] - Net profit attributable to shareholders was ¥274,738,068.68, down 48.58% from ¥534,331,688.15 year-on-year[5] - Basic earnings per share fell by 52.63% to ¥0.3432 from ¥0.7245 in the same period last year[5] - In Q1 2023, the net profit of Lier Chemical Co., Ltd. was CNY 342,029,168.28, a decrease of 42.2% compared to CNY 591,086,437.05 in Q1 2022[20] - The company's operating profit for Q1 2023 was CNY 403,195,762.83, down 42.6% from CNY 700,540,696.90 in the same period last year[20] - Total comprehensive income attributable to the parent company was CNY 274,738,068.68, down 48.6% from CNY 534,331,688.15 in Q1 2022[21] - Basic earnings per share for Q1 2023 were CNY 0.3432, a decrease of 52.6% from CNY 0.7245 in the same quarter last year[21] Cash Flow and Investments - The net cash flow from operating activities decreased by 39.47% to ¥123,955,733.40 from ¥204,771,003.87 in the previous year[5] - Cash flow from operating activities for Q1 2023 was CNY 123,955,733.40, a decline of 39.3% compared to CNY 204,771,003.87 in Q1 2022[22] - The company reported a net cash outflow from investing activities of CNY 703,479,356.00, worsening from CNY 309,682,113.96 in the previous year[23] Assets and Liabilities - Total assets increased by 6.20% to ¥13,663,798,916.24 compared to ¥12,866,345,708.15 at the end of the previous year[5] - Total liabilities increased to CNY 5,360,897,789.58 from CNY 4,483,335,442.13, an increase of 19.5%[18] - The company's equity attributable to shareholders decreased to CNY 7,148,862,668.32 from CNY 7,269,668,905.14, a decline of 1.7%[18] Operating Costs and Expenses - The total operating costs increased to CNY 2,044,281,131.94, up 6.5% from CNY 1,919,660,705.54 year-on-year[19] - The company incurred financial expenses of CNY 29,987,879.75, an increase of 21.1% from CNY 24,730,210.15 in Q1 2022[20] Research and Development - The company's R&D expenses rose by 55.49% to ¥9,752.61 from ¥6,272.32 in the previous year, indicating increased investment in innovation[11] - Research and development expenses increased to CNY 97,526,071.23, up 55.5% from CNY 62,723,198.01 in Q1 2022[20] Shareholder Information - The company recorded a total of 58,015 common shareholders at the end of the reporting period[12] Other Financial Metrics - The weighted average return on equity decreased to 3.71% from 10.19% in the previous year, indicating a decline in profitability[5] - The company reported a net profit margin decline due to increased costs, impacting overall profitability[19] - Cash and cash equivalents at the end of Q1 2023 were CNY 1,353,582,752.50, slightly down from CNY 1,333,738,748.44 at the end of Q1 2022[23] - Accounts receivable rose to CNY 1,628,660,818.38 from CNY 1,588,107,170.85 at the start of the year, indicating a growth of 2.3%[16] - Inventory decreased to CNY 1,642,894,394.51 from CNY 1,709,758,816.00, reflecting a decline of 3.9%[17] - Short-term borrowings increased significantly to CNY 295,209,305.55 from CNY 132,475,216.16, marking a rise of 123.5%[18] - The company reported a significant increase in prepayments, which rose by 63.34% to ¥14,608.30, primarily due to increased procurement of raw materials[11]

证券代码：002258 证券简称：利尔化学 公告编号：2023-010 利尔化学股份有限公司 关于举行 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 利尔化学股份有限公司（以下简称"公司"）已于2023年3月2日在 巨潮资讯网（www.cninfo.com.cn）上披露了《2022年年度报告》。 为使投资者更深入、全面地了解公司2022年度报告的内容，公司拟 于2023年3月21日（星期二）15:00-17:00举行2022年度网上业绩说 明会。 本次年度业绩说明会将采用网络远程的方式举行，投资者可登陆 深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn），进入 "云访谈"栏目参与本次年度业绩说明会。 公司拟出席本次年度业绩说明会的人员有：公司董事长尹英遂先 生，独立董事李双海先生，副总经理、董事会秘书刘军先生，财务负 责人、财务总监颜宣先生。（如有特殊情况，参会人员可能进行调整。） 为充分尊重投资者、提升交流的针对性，现就公司2022年度业 绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和 ...

Market Presence and Growth - The company has a strong market presence with a global production capacity of 80% for its main herbicide product, Benzthiazuron, indicating significant market share and growth potential[1] - The company reported a stable market for its herbicide product, Dichloropicolinic Acid, with a global production capacity of 60% and established long-term partnerships with multinational companies[1] - The company has achieved early registration and steady growth in the North American and Chinese markets for its herbicide product, Acetochlor, with a growth potential of around 30%[1] - The company maintains a competitive edge in the pesticide market, ranking among the top 10 in national pesticide sales for four consecutive years and among the top 20 global agrochemical companies[10] - The company has established a solid sales network in South America for its herbicide products, indicating a strategic market expansion[1] - The company is focusing on expanding its market presence in over 30 countries, including the USA, Brazil, and Australia, to meet diverse customer needs[29] Financial Performance - In 2022, the company achieved a consolidated revenue of CNY 10.136 billion, representing a year-on-year growth of 56.08%[12] - The net profit attributable to the parent company reached CNY 1.812 billion, marking a 69.01% increase compared to the previous year, both figures being historical highs[12] - The pesticide segment contributed CNY 9.217 billion to the total revenue, accounting for 90.93% of the total, with a year-on-year growth of 53.66%[17] - International sales revenue surged by 103.50% year-on-year, amounting to CNY 6.158 billion, which represents 60.76% of total sales[19] - The gross profit margin for the pesticide segment was 32.71%, with a slight increase of 0.16% compared to the previous year[20] Research and Development - The company has a strong focus on research and development, with a significant number of its products registered for use in various international markets, enhancing its global competitiveness[4] - The company has invested in new product development, achieving notable technological advancements and improvements in production processes[15] - The company's R&D investment reached approximately CNY 416.15 million in 2022, a 58.39% increase from CNY 262.74 million in 2021[103] - Research and development expenses rose by 48.04% to approximately CNY 365.79 million in 2022, driven by increased personnel costs and R&D investments[102] - The company has a strong patent portfolio with multiple patents related to key technologies, enhancing its R&D capabilities[93] Production and Supply Chain - The company has a comprehensive supply chain with seven production bases, ensuring a multi-base supply guarantee for its main products, including the largest production capacity for Glyphosate in China[10] - The company has made significant advancements in production efficiency for key products, including glyphosate and chlorinated pyridine, ensuring market demand is met[15] - The company’s production management is based on a "sales-driven production" principle, aligning production plans with market demand[90] Environmental and Sustainability Efforts - The company has implemented a comprehensive environmental management system, achieving ISO 14001 certification, reflecting its commitment to sustainable practices[14] - The company plans to accelerate its transformation towards green development in response to stricter environmental regulations and industry restructuring[130] - The company has increased its environmental protection investments, ensuring compliance with national standards for waste emissions[159] - The management team emphasized a commitment to sustainability, with plans to reduce carbon emissions by 25% over the next five years[186] Strategic Partnerships and Collaborations - The company has established long-term strategic partnerships with major global agrochemical firms such as Corteva, BASF, and Nufarm, enhancing its market presence[29] - A strategic partnership with a leading technology firm was announced, aimed at co-developing innovative solutions for the agricultural sector[186] Risks and Challenges - The company faces risks related to market competition, raw material supply fluctuations, and environmental regulations, which investors should be aware of[31] - Raw material costs significantly impact operating costs and gross margins, with fluctuations due to supply chain disruptions and price increases affecting profitability[159] Cash Flow and Investments - The company's net cash flow from operating activities increased by 97.12% to approximately ¥2.60 billion compared to the previous year[88] - Investment activities generated a net cash outflow of approximately ¥2.20 billion, reflecting an increase of 180.57% year-on-year[88] - The total investment amount for the reporting period was approximately CNY 2.80 billion, a 139.91% increase from the previous year[108] Corporate Governance and Management - The company emphasizes the importance of corporate governance and has made revisions to its governance documents to enhance management efficiency[139] - The company has established a dedicated audit department with four full-time auditors to oversee internal controls and financial conditions[146] - The company maintains independence from its controlling shareholder, ensuring autonomous operations in business, personnel, and finance[168] Future Outlook - The company has provided a revenue guidance of 1.8 billion RMB for the fiscal year 2023, which reflects an expected growth of 20%[186] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, with a budget allocation of 500 million RMB for this purpose[186]